Lexeo Therapeutics, Inc.
LXEO
$4.85
$0.1853.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -14.27% | -6.51% | |||
| Gross Profit | 14.27% | 6.51% | |||
| SG&A Expenses | -4.01% | 84.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.22% | 23.46% | |||
| Operating Income | 9.22% | -23.46% | |||
| Income Before Tax | 20.07% | -25.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 20.07% | -25.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.07% | -25.97% | |||
| EBIT | 9.22% | -23.46% | |||
| EBITDA | 9.26% | -23.65% | |||
| EPS Basic | 39.25% | -25.82% | |||
| Normalized Basic EPS | 31.42% | -25.66% | |||
| EPS Diluted | 39.25% | -25.82% | |||
| Normalized Diluted EPS | 31.42% | -25.66% | |||
| Average Basic Shares Outstanding | 31.59% | 0.11% | |||
| Average Diluted Shares Outstanding | 31.59% | 0.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||